Exelixis | EXEL - 負債





負債 変化する 日付
Acadia Pharmaceuticals USD 50.79M 1.39M 2026-03
Agios Pharmaceuticals USD 35.74M 4.46M 2026-03
Akebia Therapeutics USD 46.51M 7.82M 2025-03
Amgen USD 57.32B 2.72B 2026-03
AstraZeneca USD 32.24B 1.68B 2026-06
Bayer EUR 36.45B 2.93B 2025-12
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Bristol-Myers Squibb USD 46.43B 711M 2026-03
Cytokinetics USD 1.29B 4.48M 2026-03
Eisai JPY 186.08B 50.58B 2026-03
Eli Lilly USD 43.37B 867M 2026-03
Exelixis USD 165.93M 3.61M 2026-06
Genmab DKK 5.35B 5.2B 2026-03
Glaxosmithkline GBP 19.06B 1.31B 2026-03
Incyte USD 38.27M 1.16M 2026-06
Ionis Pharmaceuticals USD 1.91B 425.5M 2026-06
MacroGenics USD 36.51M 500K 2026-03
Merck USD 49.12B 222M 2026-03
Moderna USD 1.3B 7M 2026-03
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novartis USD 49.01B 2.02B 2026-06
Pfizer USD 63.19B 536M 2026-06
Puma Biotechnology USD 89.06M 55.07M 2024-06
Sanofi EUR 20.02B 1.73B 2026-03
Takeda JPY 4.94T 58.13B 2026-06
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Xencor USD 175.16M 12.58M 2026-03